Overview

Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome

Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double-blind, placebo-controlled study to determine the safety and tolerability of E5555 in subjects with Acute coronary syndrome (ACS).
Phase:
Phase 2
Details
Lead Sponsor:
Eisai Inc.